EN DE
Watch Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. stock ¥7.79, price ¥21.21, that is 63.3% below the price, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN

SH Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. logo Some data Nov 8, 2026

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.

300937 · SHE
Very expensive, in a downtrend

Our calculation puts a fair price 63% below what the stock costs today.

Low debt
Quality 54/100
Expensive Growth (revenue 5y +9.8 %/yr in CNY)
Some data
Profit last quarter 55% below a year ago.
Fair value ¥7.79 · Strongly overvalued
Loss-making · -0.3% net margin (TTM)
Negative free cash flow
Trails peers (2/12)
Narrow moat 15/100
Watch Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥64.73 ¥18.12 Fair Value ¥7.79 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range ¥18.12 – ¥64.73 · fair‑value band ¥7.34 – ¥8.16 · the ¥21.21 price screens above the ¥7.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. in your weekly email

Every Wednesday you see whether Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. provides omni-channel pharmaceutical distribution services in China. It is involved in pharmaceutical B2B e-commerce, production, wholesale, and retail businesses, as well as provides logistics services.

Show moreShow less

It offers Western medicine, Chinese patent medicine, Chinese herbal medicine slices and Chinese medicinal materials, food and health food, medical devices and non-pharmaceuticals, and other categories.

The company also provides clinics, E-commerce platform operation, logistics and distribution, management consulting, warehousing, property management, drug sale and retail chain, technology promotion and application, internet hospital, other organizational management, new media operation, equipment sales, and software development services, and information technology services, as well as engages in medical research and experimental development.

The company was founded in 2007 and is based in Chengdu, China.

Stock analysis

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) currently trades at ¥21.21, while our model-based Fair Value estimate is ¥7.79, 63% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥12.14 per share, and 0 of the 7 models we run sit above the ¥21.21 price.

Bear case: the Asset-Based group reads lowest at ¥5.24, and 7 of the 7 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ¥7.34 (bear) to ¥8.16 (bull), the price of ¥21.21 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. reported revenue of 4.5B CNY in FY2025 versus 3.4B CNY in FY2021, a compound +7.0%/yr. Reported net income was −12.9M CNY in FY2025.

Key figures

Market cap 2.0B CNY (≈ $304M) Small · P/S ratio 0.47 · EPS (TTM) ¥−0.1500 · Dividend yield 0.8% · Net margin −0.3% · Return on equity −2.2% · Return on assets (EBIT) 3.3% (5-year average) · Operating margin −1.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 50% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at −63%, 300937 screens richer than that median.

Fair Value models

Bear ¥7.34 Fair Value ¥7.79 Bull ¥8.16
Price ¥21.21 · Downside -63.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ¥5.01 ¥5.32 ¥5.75 78
ROIC Compounder ¥7.34 ¥7.79 ¥8.16 72
EPV ¥7.34 ¥7.79 ¥8.16 71
All 7 models by family
DCF Models
Owner Earnings ¥5.01 ¥5.32 ¥5.75 78
Earnings-Based
EPV ¥7.34 ¥7.79 ¥8.16 71
Multiples
EV/EBIT ¥10.18 ¥12.14 ¥14.11 66
EV/EBITDA ¥11.65 ¥14.10 ¥16.56 67
EV/Revenue ¥8.49 ¥10.29 ¥12.10 54
Asset-Based
NCAV (Graham) ¥3.46 ¥5.24 ¥6.54 55
Economic Profit
ROIC Compounder ¥7.34 ¥7.79 ¥8.16 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 44
Are margins and returns getting better?
Cashflow 21
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 52
How calm the share price moves, does not count
Price momentum 20
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.5% (2020) → 1.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300937 screens overvalued: fair value 63% below the price. Compare with JD Health International Inc →

Compare Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside −63.3% · Bottom 25%
Profitability
Return on assets −0.8% · Bottom 25%
Net margin (12 months) −0.3% · Bottom 25%
Operating margin (12 months) −1.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 4.0% · Below median
Dividend yield (12 months) 0.8% · Bottom 25%

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/B 2.47× · Pricier than median
P/S (12 months) 0.45× · Cheaper than median
EV/EBITDA 59.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 68
FUTURE (revenue growth)20 · sector 21
PAST (return on equity)0 · sector 32
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)17 · sector 58

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Al-Dawaa Medical Services Company 4163 38.18 SAR 79.49 SAR +108% vs 300937
JD Health International Inc 6618 HK$43.26 HK$75.93 +76% vs 300937
Yifeng Pharmacy Chain Co 603939 ¥27.07 ¥40.59 +50% vs 300937
Yixintang Pharmaceutical Group 002727 ¥13.48 ¥18.92 +40% vs 300937
DaShenLin Pharmaceutical Group 603233 ¥21.49 ¥25.52 +19% vs 300937
MedPlus Health Services Limited MEDPLUS ₹604.60 ₹707.67 +17% vs 300937
Anhui Huaren Health Pharmaceutical Co 301408 ¥13.81 ¥15.40 +12% vs 300937
LBX Pharmacy Chain Joint Stock Company 603883 ¥14.97 ¥16.43 +10% vs 300937
ShuYu Civilian Pharmacy Corp 301017 ¥14.34 ¥5.91 −59% vs 300937
Apotea AB APOTEA kr 104.30 kr 39.50 −62% vs 300937

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/300937

Frequently asked questions

Is Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ¥7.79 versus a price of ¥21.21, about 63% lower (overvalued).
What is the fair value of 300937?
Our model-based fair value for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is ¥7.79 (as of Nov 8, 2026), built from audited fundamentals. The current price: ¥21.21.
What is the quality score of 300937?
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Our model-based price target is the fair value of ¥7.79 (as of Nov 8, 2026) from 7 valuation models. Cautious scenario ¥7.34, optimistic scenario ¥8.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥7.79, about 63% lower versus a price of ¥21.21 (overvalued). Cautious scenario ¥7.34, optimistic scenario ¥8.16. The calculation is refreshed regularly with new filings.
What is the revenue of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. reported trailing-twelve-month revenue of about 4.5B CNY (latest available figure, as of Nov 8, 2026).
Does Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. pay a dividend?
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. currently shows a dividend yield of 0.84% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. has a dividend yield of 0.8%.
What is the intrinsic value of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. it is ¥7.79 per share (as of Nov 8, 2026), against a price of ¥21.21. It is the blended result of 7 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 300937 trades above its calculated fair value: price ¥21.21, fair value ¥7.79, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300937?
No. The price is what the market pays today (¥21.21); the fair value is what the company's own numbers justify (¥7.79). For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. the two are ¥13.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. worth?
The market values Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. at about 2.0B CNY (market capitalisation, as of Nov 8, 2026). Per share that is ¥21.21; our models calculate a fair value of ¥7.79 per share.
What do the bullish and bearish scenarios say about 300937?
Our models span a range for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.: cautious scenario ¥7.34, base ¥7.79, optimistic ¥8.16 per share (as of Nov 8, 2026, price ¥21.21). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Balance-sheet figures for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (as of Nov 8, 2026): return on equity −2.2%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 300937 from its 52-week high?
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. trades at ¥21.21, about 50% below its 52-week high of ¥42.40 and 11% above the low of ¥19.07 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.79 is for.
Which stocks are comparable to Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. stock attractive at the current price?
The data as of Nov 8, 2026: price ¥21.21, calculated fair value ¥7.79 (−63%), Quality Score 54/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300937 calculated?
We run Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. through 7 models from 5 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of ¥7.79 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
The closing price on Nov 6, 2026 was ¥21.21. Our model-based fair value is ¥7.79, about 63% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. right now?
The price sits above even our optimistic bull case (¥8.16). The favourable scenario is already priced in. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥7.34 to ¥8.16), unusually little disagreement for a valuation.

Key figures of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.

How large is the market capitalisation of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
The market capitalisation of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is 2.0B CNY (≈ $304M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
The price-to-sales ratio of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is 0.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Earnings per share at Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. are ¥−0.1500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
The dividend yield of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
The net margin of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is −0.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
The return on equity (ROE) of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is −2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
On an EBIT basis the return on assets of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
The operating margin of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is −1.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Revenue at Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is growing +4.0% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937)?
Earnings per share at Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. are growing −54.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) generate?
The free cash flow of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. is −20.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. in the live analysis

One click puts Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.